We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
표시할 이벤트가 없습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | 장 마감 후 (AMC) | — | — | — | $16.31M | — | 예정 |
Rating & price-target changes
표시할 리서치 액션이 없습니다.
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Stored first · Google News · Yahoo Finance (English)
Brainsway earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
Brainsway earnings beat by $0.02, revenue topped estimates Investing.com Nigeria
Brainsway (BWAY) director sells 17,980 shares, retains 12,500 including RSUs - Stock Titan
Brainsway (BWAY) director sells 17,980 shares, retains 12,500 including RSUs Stock Titan
H.C. Wainwright raises Brainsway stock price target on strong revenue growth - Investing.com
H.C. Wainwright raises Brainsway stock price target on strong revenue growth Investing.com
H.C. Wainwright Maintains Brainsway(BWAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
H.C. Wainwright Maintains Brainsway(BWAY.US) With Buy Rating, Raises Target Price to $17 Moomoo
BrainsWay Takes Minority Stake in Hopemark Health
BrainsWay Ltd (BRSYF) Q1 2026 Earnings Call Highlights: Record Revenue Growth and Strategic ...